このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Replimune Group 将来の成長
Future 基準チェック /26
Replimune Groupは、22.9%と53.6%でそれぞれ年率22.9%で利益と収益が成長すると予測される一方、EPSはgrowで31%年率。
主要情報
22.9%
収益成長率
31.0%
EPS成長率
Biotechs 収益成長 | 24.4% |
収益成長率 | 53.6% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Good |
最終更新日 | 13 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
3/31/2027 | 121 | -148 | -106 | N/A | 3 |
3/31/2026 | 18 | -250 | -207 | -182 | 3 |
3/31/2025 | 5 | -238 | -233 | -197 | 8 |
3/31/2024 | N/A | -216 | -191 | -185 | N/A |
12/31/2023 | N/A | -210 | -176 | -172 | N/A |
9/30/2023 | N/A | -199 | -157 | -154 | N/A |
6/30/2023 | N/A | -182 | -145 | -143 | N/A |
3/31/2023 | N/A | -174 | -130 | -128 | N/A |
12/31/2022 | N/A | -157 | -121 | -118 | N/A |
9/30/2022 | N/A | -147 | -111 | -108 | N/A |
6/30/2022 | N/A | -133 | -100 | -97 | N/A |
3/31/2022 | N/A | -118 | -85 | -82 | N/A |
12/31/2021 | N/A | -108 | -78 | -76 | N/A |
9/30/2021 | N/A | -100 | -72 | -70 | N/A |
6/30/2021 | N/A | -91 | -66 | -65 | N/A |
3/31/2021 | N/A | -81 | -64 | -61 | N/A |
12/31/2020 | N/A | -75 | -59 | -57 | N/A |
9/30/2020 | N/A | -70 | -66 | -59 | N/A |
6/30/2020 | N/A | -61 | -69 | -62 | N/A |
3/31/2020 | N/A | -53 | -67 | -61 | N/A |
12/31/2019 | N/A | -43 | -62 | -55 | N/A |
9/30/2019 | N/A | -35 | -49 | -46 | N/A |
6/30/2019 | N/A | -30 | -35 | -32 | N/A |
3/31/2019 | N/A | -31 | -28 | -25 | N/A |
12/31/2018 | N/A | -31 | -24 | -24 | N/A |
9/30/2018 | N/A | -28 | -20 | -20 | N/A |
6/30/2018 | N/A | -26 | -18 | -17 | N/A |
3/31/2018 | N/A | -20 | -16 | -16 | N/A |
12/31/2017 | N/A | -17 | N/A | -15 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: REPL今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: REPL今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: REPL今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: REPLの収益 ( 53.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: REPLの収益 ( 53.6% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: REPLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です